P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL). (23rd June 2022) - Sehn, L. H.; Hübel, K.; Luminari, S.; Salar, A.; Wahlin, B. E.; Gopal, A. K.; Bonnet, C.; Paneesha, S.; Trneny, M.; Mashegu, H.; Lihou, C.; Li, D.; et al.